RCS - Feedback PLC - Executive Appointment

FeedbackAnnouncement

06/05/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210506:nRSF6229Xa&default-theme=true

RNS Number : 6229X  Feedback PLC  06 May 2021

Reach announcement

 

Feedback plc

 

Anesh Patel appointed as CFO of Feedback Medical

 

●     Lindsay Melvin, CFO of Feedback PLC set to retire in H2 2021,
succession planning underway

 

London, 6 May 2021:  Feedback plc (AIM: FDBK, "Feedback" or the "Company"),
the specialist medical imaging technology company, is pleased to announce the
appointment of Anesh Patel as Chief Financial Officer of its trading
subsidiary, Feedback Medical Limited, with immediate effect.

 

Anesh is joining the Group as part of a succession planning programme
following Lindsay Melvin's (Chief Financial Officer of Feedback) decision to
retire during H2 2021. Anesh will work alongside Lindsay in the coming months
to ensure a smooth and orderly transition.

 

Anesh Patel joins Feedback Medical from hVIVO Limited, a subsidiary of
AIM-listed Open Orphan plc and a rapidly growing, industry-leading, clinical
services provider to pharma, biotech and government organisations where most
recently he was finance & corporate projects director.  Prior to hVIVO,
he spent seven years in investment banking where he specialised in corporate
finance advisory services, at leading banks including Société Générale and
Standard Bank.  Anesh started his professional career with Ernst & Young
in 2004 where he qualified as a chartered accountant, initially working within
the audit & assurance division before transferring to the transaction
advisory services - transaction support team for private equity clients. He
graduated from University College London (UCL) and holds an MSci. (Hons)
degree in Mathematics with Economics.

 

Rory Shaw, Chairman of Feedback, commented: "We are delighted to welcome Anesh
to the Group. He brings a wealth of wide-ranging corporate and commercial
finance experience and will provide a safe pair of hands as we begin the
process of succession planning following Lindsay's notice of retirement.
Lindsay will be very much missed, but we believe that in the coming months,
together they will set the Company in good shape to build its future - based
on the Company's flagship clinical communications platform, Bleepa."

 

-Ends-

 

Enquiries:

 

 Feedback plc                                 +44 (0) 20 3997 7634 (tel:+44%20(0)%2020%203997%207634)

 Rory Shaw, Chairman                          IR@fbk.com (mailto:IR@fbk.com)

 Allenby Capital Limited (Nominated Adviser)  +44 (0)20 3328 5656

 David Worlidge / David Hart

 Walbrook PR Ltd                              Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                              (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome/Nicholas Johnson      07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core
product, Bleepa, is a revolutionary medical imaging communications app,
providing an easy-to-use, high quality tool to enable remote and secure
communications between front-line clinicians and teams. Importantly, it is the
only CE marked medical imaging communications platform on the NHSx clinical
communications tools framework. Bleepa has unparalleled functionality for
everyday practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will
provide increasing levels of visibility as the Company grows its customer
base. With a growing distribution base and technology in place, the focus is
on leveraging key relationships in order to drive sales both in the UK and
internationally to all forms of care facilitators. As a fully certified
medical device, Bleepa aims to disrupt the medical imaging communications
market and, importantly, increase the accuracy and speed of diagnosis.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSWSUIEFSESI